Drug data last refreshed 18h ago · AI intelligence enriched 6d ago
INDOCIN (indomethacin sodium) is a nonsteroidal anti-inflammatory drug (NSAID) administered via injection for acute inflammatory and pain conditions. The injectable formulation allows rapid onset of action in hospital and acute care settings. It is primarily used for patent ductus arteriosus (PDA) closure in premature infants and acute inflammatory conditions.
As a 40-year-old mature injectable product approaching loss of exclusivity, commercial teams are likely focused on margin optimization and niche market retention rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career opportunities in INDOCIN roles are limited and oriented toward operational and defensive commercial strategies rather than growth. Working on this product offers deep expertise in mature market management, specialty pharmacy channels, and NSAID regulatory strategy, but limited upside for promotion or market expansion.
Worked on INDOCIN at Recordati? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.